Scarica l'app Stockscreener
5.44
0.37%
-0.02
Dopo l'orario di chiusura:
5.46
0.02
+0.37%
Precedente Chiudi:
$5.46
Aprire:
$5.45
Volume 24 ore:
345.75K
Relative Volume:
0.29
Capitalizzazione di mercato:
$1.22B
Reddito:
$596.48M
Utile/perdita netta:
$123.72M
Rapporto P/E:
9.9198
EPS:
0.5484
Flusso di cassa netto:
$106.59M
1 W Prestazione:
+0.74%
1M Prestazione:
+1.49%
6M Prestazione:
+41.30%
1 anno Prestazione:
+51.11%
Intervallo 1D:
$5.43
$5.47
Intervallo di 1 settimana:
$5.38
$5.48
Portata 52W:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
Confronta CVAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.44 | 1.22B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | Iniziato | SVB Securities | Outperform |
| 2023-01-19 | Aggiornamento | UBS | Neutral → Buy |
| 2023-01-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-06-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Underperform |
| 2021-04-26 | Iniziato | Guggenheim | Neutral |
| 2020-12-10 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-09-08 | Iniziato | Credit Suisse | Neutral |
| 2020-09-08 | Iniziato | Jefferies | Hold |
Mostra tutto
Curevac N V Borsa (CVAC) Ultime notizie
Is CureVac N.V. a good long term investmentMarket-beating returns - Autocar Professional
CureVac N.V.Finanzen.net - Finanzen.net
What drives CureVac N.V. stock priceFastest-growing stock picks - Autocar Professional
What analysts say about CureVac N.V. stockExponential return rates - Autocar Professional
CureVac N.V. Stock Analysis and ForecastUnmatched profit potential - jammulinksnews.com
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - MSN
CureVac: Pipeline pruning’s nasty effect - MarketScreener
CureVac N.V. (CVAC) Has Gained Over 16% In One Month. Here Is Why - Insider Monkey
Tesla chief Elon Musk teams up with Covid-19 player CureVac to build ‘RNA microfactories’ - Endpoints News
CureVac Announces Key Resolutions from Annual Shareholders Meeting - TipRanks
CureVac (CVAC) Downgraded by UBS as Acquisition Looms | CVAC Stock News - GuruFocus
CureVac Announces Key Appointments and Auditor Reappointment at Annual Meeting - TipRanks
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
BioNTech SE Announces Acquisition of CureVac N.V. - TipRanks
Germany: BioNTech to acquire CureVac in all-stock transaction - Investors in Healthcare
BioNTech to Acquire CureVac in Strategic Move - TipRanks
CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances - MarketScreener
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
BioNTech to Acquire CureVac in US$1.25 Billion All-Stock Transaction - Global Legal Chronicle
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise - simplywall.st
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead By Investing.com - Investing.com Nigeria
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of - Bluefield Daily Telegraph
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BioNTech CureVac Acquisition Boosts Cancer Drug Pipeline - Industry Leaders Magazine
CureVac (CVAC) Receives Downgrade and Price Target Reduction fro - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - GlobeNewswire
Jefferies cuts CureVac stock rating to hold on BioNTech acquisition By Investing.com - Investing.com UK
BioNTech: Oddo BHF raises target price - marketscreener.com
BioNTech to buy CureVac in USD 1.25 billion all-stock deal - Medical Dialogues
CureVac Stock: BioNTech's Billion-Dollar Takeover Bid - sharewise
Curevac N V Azioni (CVAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):